Role of Biomarker Testing in Early Detection
Biomarker testing has become a cornerstone of ovarian cancer diagnostics, offering a non-invasive and accurate method to detect malignancies at an early stage. Tests such as CA-125, HE4, and the Risk of Ovarian Malignancy Algorithm (ROMA) are increasingly utilized to identify high-risk patients and monitor treatment responses.
The efficiency and accessibility of biomarker tests are driving Ovarian Cancer Diagnostics Market Growth, as clinicians rely on these tools to improve patient prognosis. Advances in biomarker technology have enhanced specificity and sensitivity, allowing for earlier detection and reduced false positives.
Emerging markets are witnessing increased adoption due to expanding healthcare infrastructure, rising awareness campaigns, and government-led screening initiatives. Although high testing costs and limited rural availability remain
challenges, innovations are gradually making biomarker tests more affordable and accessible.
For a comprehensive report, visit Ovarian Cancer Diagnostics Market Growth.